How to reduce clinical trial site investigator turnover

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/drvarayu)
(Image: Getty/drvarayu)

Related tags: Clinical trial

CTTI has released new recommendations that can be implemented by sponsors, CROs, and others, in order to decrease the number of ‘one and done’ clinical trial site investigators.

The Clinical Trials Transformation Initiative (CTTI) released the recommendations at the Society for Clinical Research Sites (SCRS) Global Site Solutions Summit, which took place last week in Florida.

CTTI was co-founded by Duke University and the US Food and Drug Administration (FDA).

The new recommendations focus on four areas:

  1. Developing site-based research infrastructure and staff
  2. Optimizing trial execution and conduct
  3. Improving site budget and contract negotiations
  4. Discovering additional trials to conduct

Gerrit Hamre, project manager at CTTI said the evidence-based solutions can be implemented across the clinical trial enterprise, including sponsors, contract research organizations (CROs), as well as the site investigators.

By creating a supportive clinical research ecosystem—one that provides adequate infrastructure and staff, continuous training, clear operational and financial procedures, and a climate of mutual respect—investigators will feel more engaged and empowered to continue working in the clinical research space​,” he told

A balancing act

Many investigators leave clinical research due to a difficulty balancing workload, time requirements to conduct trials, data and safety reporting burdens, and financial issues, Hamre explained.

However, the professional and personal rewards of conducting research are also evident, and the ability to overcome challenges associated with clinical research is clearly articulated​,” he added.

The goal of the new recommendations is to provide “a roadmap to address these challenges and, ultimately, decrease the number of ‘one and done’ investigators​,” said Hamre.

The project was funded in part by the US FDA grant.

Related news

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers